Tumour biomarker and plasma time course data from ABIGAIL, a phase II study of 1st-line bevacizumab + chemotherapy in advanced non-squamous non-small-cell lung cancer (ns-NSCLC)

l Low baseline plasma VEGFA levels were significantly associated with longer OS – this corroborates previous data from ABIGAIL, which showed that high baseline plasma VEGFA levels had a statistically significant association with poor PFS. 3